p95HER2, a Truncated Form of the HER2 Oncoprotein, Drives an Immunosuppressive Program in HER2 Breast Cancer That Limits Trastuzumab Deruxtecan Efficacy

Researchers demonstrated that p95HER2, a truncated form of human epidermal growth factor receptor 2 (HER2), drives immune evasion in HER2-positive female breast cancer, enhancing tumor growth and conferring therapy resistance.